Current Status of the Immunomodulation and Immunomediated Therapeutic Strategies for Multiple Sclerosis by Chen, Shyi-Jou et al.
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2012, Article ID 970789, 16 pages
doi:10.1155/2012/970789
Review Article
Current Status of the Immunomodulationand Immunomediated
Therapeutic Strategies for Multiple Sclerosis
Shyi-Jou Chen,1,2 Yen-LingWang,3 Hueng-Chuen Fan,1 Wen-Tsung Lo,1 Chih-Chien Wang,1
andHuey-KangSytwu2,4,5
1Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan
2Department of Microbiology and Immunology, National Defense Medical Center, Taipei 114, Taiwan
3Center for Composite Tissue Allotransplantation, Chang Gung Memorial Hospital, Linkou, New Taipei City 333, Taiwan
4Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 114, Taiwan
5Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan
Correspondence should be addressed to Huey-Kang Sytwu, sytwu@ndmctsgh.edu.tw
Received 5 July 2011; Accepted 12 September 2011
Academic Editor: Philip Alex
Copyright © 2012 Shyi-Jou Chen et al. Thisisan open access article distributedunderthe Creative CommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Multiplesclerosis(MS)isanautoimmunediseaseofthecentralnervoussystem,andCD4+ Tcellsformthecoreimmunopathogen-
ic cascade leading to chronic inﬂammation. Traditionally, Th1 cells (interferon-γ-producing CD4+ T cells) driven by interleukin
12 (IL12) were considered to be the encephalitogenic T cells in MS and experimental autoimmune encephalomyelitis (EAE),
an animal model of MS. Currently, Th17 cells (Il17-producing CD4+ T cells) are considered to play a fundamental role in the
immunopathogenesis of EAE. This paper highlights the growing evidence that Th17 cells play the core role in the complex
adaptive immunity of EAE/MS and discusses the roles of the associated immune cells and cytokines. These constitute the modern
immunological basis for the development of novel clinical and preclinical immunomodulatory therapies for MS discussed in this
paper.
1. MultipleSclerosisand Experimental
Autoimmune Encephalomyelitis
Multiple sclerosis (MS) was initially identiﬁed in 1868 by
Charcot. This disease often begins in young adulthood with
intermittent episodes of neurological dysfunction, including
visual impairment, ataxia, motor and sensory deﬁcits, and
bowel and bladder incontinence. These are attributable to
recurrent inﬂammatory attacks on the white matter of the
brain and spinal cord, which lead to the accumulation
of perivascularly distributed inﬂammatory cells within the
brain and spinal cord white matter [1].
Beeton et al. ﬁrst established an animal model of
MS in the 1930s, when they immunized monkeys with a
central nervous system (CNS) homogenate to induce what is
now known as experimental autoimmune encephalomyelitis
(EAE) [2]. Since this pilot animal study, EAE has become
the most accepted animal model of MS. In recent decades,
pathogenic hypotheses have been investigated and novel
therapeutic agents tested in this model in the ﬁelds of CNS
inﬂammation and demyelination. Therefore, EAE provides
a valuable tool for the investigation of the T-cell-dependent
pathogenesis of autoimmune inﬂammation in the CNS and
the orchestration of the autoimmune demyelinating inﬂam-
mation in the CNS of MS patients. Mice and/or genetically
modiﬁed mice have also been of fundamental value in the
exploration of the complex pathogenesis of MS [3, 4]. EAE
is undoubtedly the best animal model in which to study
autoimmune diseases and particularly the demyelinating
diseases of the CNS, such as MS [5].
2.BasicImmunopathogenic Mechanism
andthe Role of T CellsinEAEandMS
Myelin basic protein-(MBP)-speciﬁc T cells isolated from
the peripheral lymphocytes of human individuals with MS
and encephalitogenic T cells recovered from circulating2 Clinical and Developmental Immunology
autoreactive T cells of either immunized or na¨ ıve animals
have shown that autoreactive T-cell lines that recognize the
encephalitogenic part of MBP in vitro can be distinguished
from an unprimed rat T-cell population. This conﬁrms that
autoreactive T cells play a central role in the pathology of MS
[6–8]. EAE can also be induced by adoptively transferring
an expanded population of myelin-reactive encephalitogenic
CD4+ (T helper [Th]) cells, which allows the further
dissection of the immunopathogenic potency of diﬀerent
encephalitogenic CD4+ cell populations [9].
In the 1990s, Mosmann and Coﬀman postulated that
Th cells can be classiﬁed into two distinct subsets, Th1
and Th2. Th1 cells produce large quantities of interferon
γ (IFNγ), driven by interleukin 12 (IL12), which promotes
cellular immunity directed against intracellular pathogens.
Alternatively, Th2 cells, which secrete IL4, IL5, IL13, and
IL25,areessentialinthedestructionofextracellularparasites
and the mediation of humoral immunity [10, 11]. Self-
reactive Th1 clones derived in vitro are capable of adoptively
t r a n s f e r r i n gE A Et on a ¨ ıve recipients [12]. Increased levels
of Th1 cytokines are particularly evident during EAE/MS
relapse, whereas increased Th2 cytokines are found during
remission in MS patients when compared with control levels
[13]. Clinical and hematological symptoms are exacerbated
in relapsing/remitting MS patients following the adminis-
tration of IFNγ, and this is also observed in other Th1-
type diseases, whereas it is less apparent in Th2 diseases
[14, 15]. Th1 cells were earlier thought to be pathogenic
T cells, whereas Th2 cells were thought to confer an anti-
inﬂammatory potential, constituting protective T cells in
both MS and EAE [16–19].
However, this clear-cut immunodysregulation of the
Th1/Th2 balance in EAE and MS may be part of a hidden
complex of interactions underlying EAE and MS [20]. The
Th1-driven nature of the EAE/MS disease was challenged
by the ﬁnding that IFNγ-a n dI F N γ-receptor-deﬁcient mice,
as well as mice that lack other molecules involved in Th1
diﬀerentiation,suchasIL12p35,IL12receptorβ2(IL12Rβ2),
and IL18, were not protected from EAE, but instead were
more susceptible to the disease [21–25]. Unexpectedly,
mice deﬁcient in IL12α (IL12p35), a component of the
Th1 paradigm, are vulnerable to EAE. Similarly, IL12Rβ2-
deﬁcient mice develop more severe clinical manifestations
of EAE, whereas IL12p40-deﬁcient mice are resistant to EAE
[23,24,26].Thesediscrepanciesandconﬂictingdataindicate
that an imbalance in the Th1/Th2 milieu cannot explain the
overallimmunopathogenicmechanismsunderlyingEAEand
MS.
3. Immunopathogenic Role of Th17 Cellsand
CytokinesinEAE/MS
p19, a novel cytokine heavy-chain homologue of the IL6
subfamily, was discovered as a computational sequence [27].
When the p19 chain is linked to the p40 chain, a subunit of
IL12 (another subunit of the IL12 heterodimers is the p35
chain), it forms a novel cytokine designated IL23. Therefore,
the deletion of IL12p40 will aﬀect the functions of both
IL12 and IL23. Cua and colleagues veriﬁed that Il23 but
not Il12 is essential for the induction of EAE by generating
Il23p19 knockout (KO) mice and comparing them with
IL12p35 KO mice [28]. Furthermore, an IL17-producing T-
cell subset, driven and expanded by IL23, can pathogenically
induce EAE when adoptively transferred into na¨ ıve wild-
type mice [29, 30]. These IL17-producing T cells were
dramatically reduced in the CNS of IL23p19-deﬁcient mice.
Basedonthesestudies,researchersconﬁdentlysuggestedthat
IL17-producing CD4+ T cells are a distinct and novel Th
subset that exacerbates autoimmunity, and designated them
Th17 cells [31, 32]. Th17 cells are a Th-cell subset distinct
from Th1 and Th2 cells in terms of their diﬀerentiation,
expansion, and eﬀector functions [33, 34]. The discovery of
Th17 cells further clariﬁes the cytokine proﬁle of MS [35].
Recently, the levels of IL17 produced by MBP-stimulated
peripheral blood cells obtained from MS patients or controls
wereshowntocorrelatewiththeactivelesionsinMSpatients
observed with magnetic resonance imaging (MRI) [36].
Like other Th subsets, the Th17 lineage is activated by
a speciﬁc cytokine milieu. However, IL23 cannot produce
Th 17 cells de novo from na¨ ıve T cells, and the IL23
receptor (IL23R) is not expressed on na¨ ıve T cells [37].
Transforming growth factor β (TGFβ) upregulates IL23R
expression, thereby conferring responsiveness to IL23, which
conﬁrms that TGFβ is a critical cytokine in the commitment
to Th17 expansion in vitro and in vivo [38]. In mice,
TGFβtogetherwithIL6canactivateantigen-responsivena¨ ıve
CD4+ T cells to develop into Th17 cells [39]. In humans,
na¨ ıveCD4+ cellsexposedtoIL6,TGFβ,andIL21candev elop
into Th17 cells, and the production of IL23 plays a role
in maintaining these Th17 cells [40, 41]. Altogether, Th17
cells require IL23, TGFβ, IL6, and IL1 for their generation.
Th17 cells produce IL17A and IL17F, which are upregulated
in chronic lesions [42] ,a n dI L 2 2 ,w h i c hi sa l s oi n v o l v e d
in the pathogenesis of MS. Thus, Th17 cells are a recently
discovered, unique Th lineage that produces a repertoire
of signature cytokines, including IL17A, IL17F, IL21, and
IL22, that are essential for the development of autoimmune
d i s e a s e ss u c ha sM S[ 43].
The discovery of transcription factors that are key regu-
lators of the cytokine expression required to launch lineage-
speciﬁc transcriptional programs has greatly extended our
understanding of Th-cell lineage commitment [44]. It has
been shown that T-bet and STAT4 program the commitment
of the Th1 lineage and Th1 cytokine production [45],
whereas GATA-binding protein 3 (GATA3) and STAT6 drive
Th2populationexpansionandTh2cytokineproduction[46,
47].TheT-betandSTAT4(necessaryforTh1diﬀerentiation)
transcription factors are important in the diﬀerentiation of
autoimmune T cells in the EAE model [48], and T-bet-
and STAT4-deﬁcient mice are resistant to EAE. However,
these transcription factors do not mediate the induction
of Th17 cells. Instead, in a unique inductive milieu, Th17
diﬀerentiation is driven by distinct transcription factors:
retinoic acid receptor-related orphan receptor-γt( R o r γt)
and Rorα [33, 34]. Stat3 deletion in T cells also prevents
autoimmune uveitis and EAE and increases the expression of
IL10 and forkhead box P3 (FoxP3) [49], and the expression
of FoxP3 programs the development and functions of TregClinical and Developmental Immunology 3
cells [50]. In humans, IL23 and IL1β also induce the
development of Th17 cells expressing IL17A, IL17F, IL22,
IL26, IFNγ, the chemokine CCL20, and the transcription
factorRORγ [51–53],asillustratedinFigure 1(adaptedfrom
Hirota et al. [54]).
Recent microarray studies of lesions in MS patients
demonstrated an increased expression of IL17, conﬁrming
that Th17 cells play an important role in the development of
inﬂammationanddemyelinationandintheeventualdamage
of the CNS. IL17 is a recently described cytokine produced in
humans almost exclusively by activated memory T cells and
can induce the production of proinﬂammatory cytokines
and chemokines from parenchymal cells and macrophages.
Patients with MS have greater numbers of IL17-mRNA-
expressing mononuclear cells in the cerebrospinal ﬂuid
(CSF) than in the blood. Previously, no increase in the
numbers and expression of IL17 mRNA by mononuclear
cells isolated from the CSF was observed in patients with
MS, but higher levels of IL17 mRNA were observed in
the CSF than in the blood, with the highest levels in the
blood detected during clinical exacerbations [56]. These data
conﬁrm the pivotal role of IL17 in MS both peripherally and
centrally.
4.RecruitedandResidential InnateImmune
Cells in EAE and MS
Myelin is expressed in the circulation, and other CNS anti-
gensare thoughttobe expressed in the cervicallymphnodes,
which can trigger the conversion of autoaggressive myelin-
reactive T cells to pathogenic T cells. Adhesion molecules,
the integrins, allow these myelin-reactive T cells to penetrate
the blood-brain barrier (BBB) under inﬂammatory condi-
tions, and in this way, activated and memory T cells can
enter the CNS [57]. Autoaggressive myelin-reactive T cells
migrate into the CNS, where they recognize their cognate
target antigens, and the movement of antigen-presenting
cells (APCs) into the CNS is essential for lymphocyte
reactivation within the CNS compartment and the initiation
of the inﬂammatory cascade in the development of EAE
[58]. Subsequently, inﬂammatory and immune cells, such
as granulocytes and macrophages, are attracted into the
CNS parenchyma, where they mediate tissue inﬂammation,
leading to demyelination and tissue damage [59].
Thebrainwasformerlyconsideredanimmunoprivileged
organ, but this perspective has been revised in the last two
decades [60]. Today, we understand that any damage to
the CNS can activate immune cells in situ in the CNS,
particularly microglial cells. Deshpande et al. demonstrated
the transient inactivation of microglial cells via a cell-speciﬁc
deﬁciency of CD40 expression, indicating that microglial
cells are crucial for maintaining the autoimmune responses
in the CNS [61]. The major histocompatibility complex
(MHC, also known as “human leukocyte antigens” in
humans) class II molecules are only displayed on specialized
APCs (e.g., dendritic cells [DCs], B cells, and macrophages),
whereas MHC class I molecules are expressed by all cells
in the inﬂammatory milieu of the CNS [62]. Microglial
cells upregulate the expression of MHC and costimulatory
molecules to initiate the generation and maintenance of the
inﬂammatory milieu. DCs seem to play a critical role in
antigen presentation to invading T cells and in the release
of cytokines and chemokines, thereby guiding the entry of
monocytes, lymphocytes, and cells with a phenotype similar
to that of DCs into the lesion [63].
Th cells recruit macrophages, which release proinﬂam-
matory cytokines and destructive molecules (such as nitric
oxide [NO], IL1, IL6, tumor necrosis factor α [TNFα],
and matrix metalloproteinases (MMPs]), and CD8+ Tc e l l s
also directly attack MHC class I-expressing cells, such as
oligodendrocytes and neurons [64, 65]. The secretion of
destructive molecules, such as NO and TNFα, and the
degradation of myelin are consequences of this cascade. TNF
receptor 1 (TNFR1) but not TNFR2 signaling is critical for
demyelination and the limitation of T-cell responses dur-
ing immune-mediated CNS disease [66]. This complicated
process triggers the recruitment of innate immune cells,
generally consisting of T cells, macrophages, and microglia,
which in turn mediate demyelination, axonal damage, and
lesions.
5.Th17 andImmune CellsInSitu
In autopsy samples from MS patients, the expression of IL17
is evident in perivascular lymphocytes and in astrocytes and
oligodendrocytes located in the active areas of CNS lesions.
IL17R is also identiﬁable in acute and chronic MS plaques
of patients with MS, suggesting the enrichment of Th17
and CD8+ T cells in active MS lesions, and conﬁrming an
important role for IL17 in the pathogenesis of MS [67].
Th17 cells are identiﬁed by their expression of IL23R and the
memory T-cell marker CD45RO in situ. Other markers that
have been investigated including the chemokine receptor,
CCR6, and RORC variant 2, which is a central transcription
factor for Th17-cell development [42, 68]. Microarray analy-
sis of MS lesions has also demonstrated increased transcripts
of genes encoding inﬂammatory cytokines, particularly IL6,
IL17, and IFNγ and associated downstream pathways [56].
A signiﬁcant increase in IL23 mRNA and protein expression
is found in lesion tissues compared with nonlesion tissues.
Activated macrophages/microglia have been shown to be
important sourcesofIL23p19inactiveandchronicallyactive
MS lesions. IL23p19-expressing mature DCs are preferen-
tially located in the perivascular cuﬀs of active lesions. This
data on the expression of IL23p19 in MS lesions improves
our understanding of the pathogenesis of MS [69].
There is also evidence that MS endothelial cells express
high levels of IL17R and are more permeable to IL17
than are non-MS endothelial cells. Perivascular DCs also
express high levels of granzyme B in inﬂammatory lesions,
polarizing na¨ ıve CD4+ T cells into Th17 cells. These Th17
cells transmigrate eﬃciently across BBB endothelial cells
(BBB-ECs),leadingtothedestructionofhumanneuronsand
initiating CNS inﬂammation through Th-cell recruitment
[70]. Similarly, the expression of IL17R and IL22R on BBB-
ECs has been examined in MS lesions, and IL17 and IL22
have been shown to disrupt BBB tight junctions in vitro and4 Clinical and Developmental Immunology
Figure 1: Current schedule of T-helper-cell diﬀerentiation. When na¨ ıve CD4+TCRαβ+ T lymphocytes, classiﬁed by their low expression of
CD44, absence of CD25, and high levels of CD62L, encounter their cognate antigens, they can diﬀerentiate into several previously identiﬁed
eﬀector subsets. It is likely that several “master” transcription factors, individually required for T-cell diﬀerentiation towards one of the
end eﬀector stages, are initially expressed upon engagement of the TCR with costimulatory receptors. Each transcription factor drives a
speciﬁc set of genes required for lineage commitment and the expression of signature cytokines and negatively aﬀects alternative pathways.
However, the local microenvironment is the driving force that determines the outcome of the diﬀerentiation course. Th1 cells are established
in the presence of IFNγ and IL12 and signaling via STAT1 and STAT4, resulting in the expression of the master transcription factor T bet.
Th2 cells depend on IL4 and STAT6 for the increased expression of GATA3, whereas the simultaneous presence of TGFβ results in the
development of Th9 cells, utilizing an undeﬁned master transcription factor. The presence of TGFβ, with IL2 signaling via STAT5, is known
to generate, at least in vitro, inducible Treg, which utilize FOXP3 like those Treg generated in the thymus. Again, it is TGFβ in combination
with IL6 signaling via STAT3 that drives the expression of RORγt, resulting in the diﬀerentiation of Th17 cells. However, the initiation of the
developmental program of these T helper subsets may not be completed in the presence of only these driving cytokines. Several additional
factors may be required for their subsequent functional maturation or may be responsible for the ﬁne tuning of their eﬀector phases. Several
of these factors are indicated, together with the characteristic cytokine proﬁles of each subset (adapted from [54]).
in vivo. IL6 transsignaling may also play a role in the autoim-
mune inﬂammation of the CNS, mainly by regulating the
early expression of adhesion molecules, possibly via cellular
networks at the BBB [71]. Ifergan et al. demonstrated that
a subset of CD14+ monocytes migrate across the inﬂamed
human BBB and diﬀerentiate into CD83+CD209+ DCs
under the inﬂuence of BBB-secreted TGFβ and granulocyte-
macrophage colony-stimulating factor (GM-CSF). These
DCs can produce IL12p70, TGFβ, and IL6 and promote the
proliferation and expansion of distinct populations of Th1
andTh17cells.TheabundanceofsuchDCsinsituisstrongly
associated with microvascular BBB-ECs within acute MS
lesions and with a signiﬁcant number of Th17 cells in the
perivascular inﬁltrate [72].
Astrocytes play signiﬁcant physiological roles in CNS
homeostasis and act as a bridge between the CNS and the
immune system. Astrocytes also contribute to the complex
interactions during CNS inﬂammation. IL17 functions in
a synergistic manner with IL6 to induce IL6 expression in
astrocytes. Astrocytes upregulate the expression of IL17 and
IFNγ genes and proteins in T cells, which is consistent with
the astrocytes’ capacity to express IL23 subunit p19 and the
common IL12/IL23 subunit p40, but not IL12 subunit p35
when these two cell types are cocultured [73]. Das Sarma et
al. demonstrated increased IL17RA expression in the CNS of
mice with EAE and the constitutive expression of functional
IL17RA in mouse CNS tissues. They also identiﬁed the
expression of IL17RA in both astrocytes and microglia inClinical and Developmental Immunology 5
vitro. In that study, the secretion of the chemokines Mcp1,
Mcp5, Mip2, and CxcL1 was upregulated in these cells,
suggesting that the upregulation of chemokines by glial
cells is the result of IL17A signaling through constitutively
expressed IL17RA [74].
Ma et al. demonstrated that the suppressor of cytokine
signaling 3 (Socs3) participates in IL17 functions in the
CNS as a negative feedback regulator, using mouse models
of Socs3 small interfering RNA (siRNA) knockdown and
Socs3 deletion. These mice with loss of Socs3 function
showed enhanced IL17 and IL6 signaling in astrocytesvia the
activation of the NF-κB and Mapk pathways, indicating that
astrocytes can act as a target of Th17 cells and IL17 in the
CNS [75]. Similarly, Kang et al. constructed speciﬁc deletion
mutants of Act1, a critical component required for IL17
signaling,inmicewithEAEtoexamineCNSinﬂammationin
endothelial cells, macrophages, microglia, and the neuroec-
toderm (neurons, astrocytes, and oligodendrocytes). In these
Act1-deﬁcient mice, Th17 cells showed normal inﬁltration
into the CNS but failed to recruit lymphocytes, neutrophils,
and macrophages. Therefore, astrocytes are critical in IL17–
Act1-mediated leukocyte recruitment during EAE [76].
Interestingly, Merkler et al. demonstrated that macro-
phages respond to the Th1 milieu and neutrophils respond
to Th17 cytokines in a marmoset monkey model of EAE.
They also showed dense accumulations of T and B lym-
phocytes, MHC-II-expressing macrophages/microglia, and
early activated macrophages at the sites of perivascular and
parenchymal lesions in the neocortex and subcortical white
matter, indicating that the inﬂammatory response, especially
macrophage and microglia activation, may be regulated
diﬀerently in the gray matter areas of the primate brain
[77].
In summary, DCs in the peripheral tissues and microglia
in the CNS are responsible for cytokine polarization and the
expansion of Th17 cells. The complex interactions of Th17
cells with diﬀerent DCs, such as microglia, astrocytes, and
peripheral DCs (including neutrophils and macrophages),
all contribute to the immunopathogenesis of EAE and
MS.
6. ReciprocalInteractions of Cytokines on Th
SubsetsinEAE/MS
IL1R KO mice have impaired Th17 cells and are protected
from EAE [78], and IL1β increases the susceptibility to and
progression of relapse onset in MS [79], implying a role for
IL1β in the development of EAE and MS. EAE was abolished
by a virus-expressing IL4 but not by a virus-expressing
IL10 in chronic relapsing EAE. Therefore, the cytokine
environment was converted from a disease-promoting IL23-
producing condition to a disease-limiting IL4-producing
condition by the local expression of IL4 from a Herpes
simplex virus vector delivered to the brain [80]. Moreover,
the increased expression of IL4 in glial cells was associated
with the reduced severity of EAE [81], suggesting that the
upregulation of Th2 cytokines inhibits the propagation of
theinﬂammationofEAE/MSbyencephalitogenicTh17cells.
CD4+CD25+Foxp3+ T cells, well-known regulatory T cells
(Tregs), retain the potential to inhibit the autoimmune
response, and protect against inﬂammatory injury. TGFβ is
a key cytokine in the generation of Tregs. Tregs are not only
primarilyinvolvedintheregulationofTh17cellsbutcanalso
regulate the functions of Th1/Th2 cells [82]. A distinction
has been drawn between the generation of pathogenic Th17
cells that induce autoimmunity and the generation of Tregs
that inhibit autoimmune tissue injury [39].
Although EAE was once considered a classical Th1 dis-
ease, it has been proposed that it is predominantly Th17
driven. Recently, Singh et al. demonstrated that the overex-
pression of IL17 in T cells did not exacerbate EAE. Moreover,
genetic and antibody studies have indicated that the absence
of IL17A or IL17F does not reduce the incidence or severity
of EAE. The collective ﬁndings of IL17 and IFNγ studies
indicate that their roles may depend on the nature of the
immune response and that the IL17 that occurs in the
brain may overcome the inhibitory eﬀect of IFNγ,w h i c h
generally prevents inﬂammation at that site [83]. When
pure Th17 cells from myelin oligodendrocyte glycoprotein-
(MOG-) immunized mice, polarized with TGFβ to deplete
anyIFNγ production,areadoptivelytransferredtomice,they
do not induce EAE, suggesting that the reciprocal interac-
tions among Th17-related cytokines enrol and activate the
involvement of associated immune cells. Interestingly, when
Th17 cells are combined with Th1 cells, they can fully induce
EAE disease [84]. Liu et al. also demonstrated that the loss of
STAT3byThcellsresultsinanintrinsicdevelopmentaldefect
that renders STAT3−/− mice resistant to CNS inﬂammatory
diseases. STAT3 is required for the production of IL17
by Th17 cells, the generation of double positive T cells
expressing IL17 and IFNγ,a n dTc e l lt r a ﬃcking into CNS
tissues. This suggests that STAT3 may be a therapeutic target
for modulating CNS autoimmune diseases, and that Th1
cells can facilitate the entrance of Th17 cells into the CNS
during EAE [85].
An encephalitogenic Th1 cell line that induces the
recruitment of host Th17 cells to the CNS during the initi-
ation of EAE has been reported [49]. Stromnes et al. showed
signiﬁcant diﬀerences in the regulation of inﬂammation in
the brain and spinal cord, depending on diﬀerent Th17/Th1
ratios, by demonstrating that speciﬁc T-cell populations
targeting diﬀerent myelin epitopes are characterized by
different Th17/Th1 ratios in EAE [86]. Therefore, Th1 cells
have the potential to reciprocally regulate Th17 cells during
EAE.
IL21 is a type I four-α-helix bundle cytokine that belongs
to the IL2 family and functions as a “growth hormone”-
like cytokine. After the antigen-responsive diﬀerentiation
phase,Th17cellsentertheampliﬁcationstage,andIL21plays
a pivotal role in the expansion and diﬀerentiation of the
Th17 lineage, providing an autocrine and paracrine stimulus
for Th17 cells [41, 87]. During clonal expansion, IL21 also
promotes IL23R expression in diﬀerentiated Th17 cells,
whichplaysanimportantroleinthestabilizationoftheTh17
lineage in the presence of IL23 [88]. Although no eﬀectswere
observed when Il21 was administered after EAE progression,
the administration of IL21 boosted natural killer (NK)6 Clinical and Developmental Immunology
cell functions before the induction of EAE, including the
secretion of Ifnγ. Therefore, IL21, by aﬀecting NK cells, has
various eﬀects during the initiation and progression of EAE
[89].
Alternatively, IL27, an IL12/IL23 family member, is a
negative regulator of Th17 cell diﬀerentiation and can pre-
vent inﬂammatory demyelination in the EAE model [44].
IL27 drives the expansion and diﬀerentiation of IL10-
producing Tr1 cells by inducing the expression of three
key molecules: the transcription factor c-MAF, the cytokine
IL21, and ICOS. Moreover, IL27-driven c-MAF expression
transactivates the production of IL21, which acts as an
autocrine growth factor for the expansion and/or main-
tenance of IL27-induced Tr1 cells. ICOS also promotes
IL27-driven Tr1 cells. Each of these elements is essential,
because the loss of c-MAF, IL21 signaling, or ICOS reduces
the frequency of IL27-induced diﬀerentiation of Tr1 cells
(Figure 1)[ 90]. Exacerbation of EAE was demonstrated in
IL27-deﬁcient mice, and interestingly, Il27-treated mice had
markedly reduced CNS inﬂammatory inﬁltration, indicating
the downregulation of Th17 phenomena [91].
Recently, a novel eﬀector T-cell subset, Th9 cells, has
been identiﬁed, and the ability of this T-cell subset to induce
EAE is currently being investigated. J¨ ager et al. generated
Mog-speciﬁc Th17, Th1, Th2, and Th9 cells in vitro to
directly characterize their encephalitogenic potency after
their adoptive transfer. They found that Mog-speciﬁc Th1,
Th17, and Th9 cells, but not Th2 cells, induce EAE. Inter-
estingly, each T-cell subset induced disease in a distinct
pathological manner, suggesting that the diﬀerent eﬀector
Th subsets that induce EAE do so diﬀerently and implying
that the pathological heterogeneity in MS lesions might
be partly attributable to various characteristics of myelin-
reactive eﬀector T cells [92]. The authors also suggested that
MS might be a disease caused by multiple distinct myelin-
reactive eﬀector cells. The disease induced by Th17 cells in
someanimalsexhibitedsymptomsatypicalofEAE,including
ataxia,severeimbalance,andweightlossassociatedwithhigh
mortality.Someanimalshadamixtureofatypicalandtypical
EAE symptoms. When cells were recovered from the CNS, it
appeared that the transferred Th9 cells produced IFNγ.T h e
identities of the other cell populations did not seem to drift
after their in vivo transfer [93].
Nowak et al. recently demonstrated that like other T cells
cultured in the presence of TGFβ, Th17 cells produce
IL9. Th17 cells generated in vitro with IL6 and TGFβ
and ex vivo-puriﬁed Th17 cells both produced IL9. Data
show that IL9 neutralization and IL9R deﬁciency attenuate
the disease, and this correlated with reductions in Th17
cells and IL6-producing macrophages in the CNS. These
authors also conﬁrmed the role of IL9 in the development
and progression of EAE and implicated Il9 as a Th17-
derived cytokine that contributes to inﬂammatory disease
[94].
Together, Th2 cells, Tr1 cells, and Tregs exert repressive
eﬀects on Th17 cells, and Th9 cells have a stimulatory eﬀect
on Th17 cells, suppressing EAE and MS. However, Th1 cells
play dual roles in EAE.
7. ClinicalApplications, Limitations,andthe
FutureofImmunomediatedTherapiesforMS
Our understanding of the pathophysiology and neurode-
generative processes of MS has led to the development of
novel therapeutic strategies. Since the early 1990s, disease-
modifying drugs have been introduced for the selective
management of MS, including IFNβ and glatiramer acetate
(GA), which have become the standard treatment for relaps-
ing/remitting MS [95]. Most recommendations previously
made by the Multiple Sclerosis Therapy Consensus Group
(MSTCG) on the use of disease-modifying drug therapies
remain valid [96,97].HermmerandHartunghavepublished
an apparent review of the development of rational therapies
in MS [98]. Therefore, we will discuss four domains of
novel immunomediated therapeutics used for MS and their
current status.
The ﬁrst domain includes immunosuppressive agents,
such as mitoxantrone, laquinimod (ABR-215062), cladribine
(Mylinax ), and teriﬂunomide (probably via the suppres-
sion of TNFα and IL2 production). The second domain
includes immunomodulatory agents: (1) cytokine inhibitors
such as IFNβ; (2) agents that deplete speciﬁc immune
cell subsets, such as alemtuzumab (a human monoclonal
antibody [mAb] that targets CD52 expressed by T and B
cells, producing long-term T-cell depletion) [99, 100]a n d
rituximab (which targets CD20 to deplete human B cells)
[99, 101]; (3) agents that selectively block coreceptors and
costimulators, such as daclizumab (an anti-CD25 mAb that
inhibits activated T cells and induces regulatory immune
cells) [102]. The third domain involves the development
of migration-modifying therapies: (1) agents that aﬀect
adhesion molecules, such as natalizumab (an mAb that
blocks very late antigen 4 [VLA-4]) and (2) sphingosine 1-
phosphate receptor (S1PR) agonists: ﬁngolimod (FTY720).
The fourth domain includes neuroprotective agents asso-
ciated with immunomodulation, including broad-spectrum
immunomodulators such as statins, PPAR agonists (e.g.,
pioglitazone, gemﬁbrozil), the sex hormone estriol (E3),
fumarate, minocycline, and erythropoietin (EPO), all of
which have been eﬀective in the treatment of both EAE, and
MS. IFNβ has been clinically introduced to treat patients
withMSbasedonitsabilitytoshiftaTh1-mediatedresponse
to a Th2-mediated response [92]. However, microarray
studies have indicated that a number of genes in patients
with MS are upregulated by the cytokines associated with
the diﬀerentiation of cells into Th1 lymphocytes rather than
into Th2 lymphocytes, suggesting that this shift may not be
the only therapeutic mechanism of IFNβ in MS [103]. IFNβ
therapy also reduces IL23 mRNA levels [104]. IFNβ inhibits
human Th17 cell diﬀerentiation, so the Th17 axis could be
another target of IFNβ therapy [105]. IFNβ-mediated IL27
production by innate immune cells has been shown to play
ac r i t i c a lr o l ei nt h ei m m u n o r e g u l a t o r yr o l eo fI F N β in
EAE by inhibiting Th17 cells in EAE mice and MS patients
[91, 106, 107]. Besides, Galligan et al. evidence further that
IFNβ(−/−) mice exhibited an earlier disease onset and a
more rapid progression of EAE compared to IFNβ(+/+)
mice of EAE and IFNβ(−/−) mice of EAE had increasedClinical and Developmental Immunology 7
numbers of CD11b(+) leukocytes inﬁltrating aﬀected brains
and an increased percentage of Th17 cells in the CNS with
augmentation of autoreactive T cells,suggesting that IFN-
β acts to suppress the production of autoimmune-inducing
Th17 cells during the development of disease as well as
modulating proinﬂammatory [108]. In addition, the thera-
peuticeﬀectofIFNβ isprobablyattributabletotheinduction
of the regulatory cytokine IL10 [104]. Furthermore, Axtell
et al. design a delicate study to further clarify the role of
IFNβ in MS/EAE [109]. Likewise, They demonstrate that
IFNβ was eﬀective in reducing EAE symptoms transferred
by Th1 cells transfer but exacerbated disease by Th17 cells
transfer and eﬀective treatment of IFNβ in Th1-induced
EAEcorrelatedwithaugmentedIL10production;diﬀerently,
in Th17-induced EAE, the amount of IL10 was unaﬀected
by treatment of IFNβ. Likewise, a high IL17F level in the
serum of people with RRMS is associated with fail of IFNβ
therapy. This characteristic of IFNβ might contribute to
explore some logical biomarkers for predictive assessment
of the response to a popular therapy for MS [109, 110].
Although, B cells may have a dual role in the pathogenesis of
MS that they contribute to the induction of the autoimmune
response but also mediate the resolution of the CNS
inﬂammatory inﬁltrate [111, 112]. However, Ramgolam et
al. demonstrate further that supernatants transferred from
IFNβ-1b-treated B cells inhibited Th17 cell diﬀerentiation,
as they suppressed gene expression of the RORC and IL-
17A and secretion of IL-17A. Likewise, IFNβ-1b also induces
B cells’ IL-10 secretion which may mediate their regulatory
potent [113]. Thus, IFNβ-1b exerts its therapeutic eﬀects at
least in part by targeting B cells’ functions that contribute
to the autoimmune pathogenesis of RR MS, which may
uncover extra mechanisms of the B-cell contribution to the
autoimmune eﬀects and provide novel targets for future
selective treatment of MS [113].
Glatiramer acetate (GA; Copaxone; copolymer 1) exerts
a clinical response in MS patients via its modulation of
IFNγ and IL4 by reducing the expression of IFNγ and
ensuring the stable expression of IL4 in anti-CD3/CD28-
stimulated peripheral blood mononuclear cells (PBMCs)
[114]. Moreover, GA enhances the suppressive eﬀects of
Tregs in both EAE and MS [115, 116]. Studies of human
DCs have shown that GA modulates the production of
inﬂammatorymediatorswithoutaﬀectingDCmaturationor
immunostimulatory potential. DCs exposed to GA secrete
low levels of the Th1-polarizing factor IL12p70 in response
to lipopolysaccharide and triggering of the CD40 ligand
[117]. Human DCs exposed to GA also induce IL4-secreting
eﬀector Th2 cells and increase their expression of IL10 [118].
These results show that APCs, including DCs, are essential
fortheGA-mediatedshiftinTh-cellphenotypesandindicate
that DCs are an important target of the immunomodulatory
eﬀects of GA.
Patients with MS show a threefold to fourfold increase
in the expression of the α4 subunit of the integrin VLA-
4, which is normally expressed on activated lymphocytes,
monocytes, and other cell types in the CSF and circulation
[119]. Elovaara et al. conﬁrmed that methylprednisolone
reduces the adhesion molecules in the blood and CSF in
patients with MS [120], implying that targeting leukocyte
traﬃcking may be a possible therapeutic strategy for MS
[121]. Therefore, natalizumab, a humanized mAb directed
against the VLA-4 adhesion complex, has been introduced
into the treatment of MS and reduces the risk of sustained
progression of disability and the rate of clinical relapse in
patients with relapsing MS [122]. However, during clini-
cal trials, two natalizumab-treated MS patients developed
progressive multifocal leukoencephalopathy (PML), which
resulted in the voluntary removal of the drug from the
market in February 2005 [123, 124]. A retrospective safety
evaluation was subsequently conducted, and natalizumab
was consequently returned to the market as a monotherapy
in July 2006 for the treatment of relapsing MS; however,
there were 111 cases of PML reported subsequently in
natalizumab-treated MS patients as of April 2011 [125].
More evidently, the risk of developing PML for a MS patient
on natalizumab (Tysabri) is almost 100 times higher if the
patient (1) has been taking the drug for more than two
years, (2) has a prior history of immunosuppressant use,
and (3) tests positive for antibodies to the JC virus [126],
compared to a patient with none of these three risk factors
[127]. Instead, there is currently no convincing evidence that
natalizumab-associated PML is restricted to combination
therapy with other disease-modifying or immunosuppres-
sive agents [128]. Nevertheless, natalizumab use must be
restricted to the indicated patients.
Mitoxantrone, a cytotoxic drug with immunomodula-
tory properties, is used to treat progressive forms of MS
[129]. Mitoxantrone increases the ex vivo production of
the Th2 cytokines IL4 and IL5, but with no signiﬁcant
changes in IFNγ,T N F α, IL10, or IL17 expression by PBMCs
or CD4+ T cells, indicating that the immunomodulation
aﬀorded by mitoxantrone treatment in MS acts through the
enhancement of Th2-type cytokines [130].
Currently, a head-to-head race for approval had initially
developed between two under spotlight oral immunomod-
ulatory agents—ﬁngolimod and cladribine (Figure 2)[ 131].
Fingolimod (FTY720/Gilenya, Novartis), an S1PR modula-
tor [132], is under the spotlight because it has completed
phase III trials [133] and has been approved by the US
Food and Drug Administration as the ﬁrst oral, ﬁrst-line
treatment for relapsing MS [134, 135]. S1PR is mainly
expressed by immune cells, neuronal cells, endothelial cells,
and smooth muscle cells [136–139] .T h ek e yr o l e so fS 1 P R
in angiogenesis, neurogenesis, and the regulation of immune
cell traﬃcking, endothelial barrier function, and vascular
tone were demonstrated with the genetic deletion of S1pr
in a murine model [140–142]. The immunomodulatory
eﬀect of ﬁngolimod acts in two pathways. In one pathway,
it inhibits the function of S1PR, which facilitates the
CC-chemokine receptor 7-(CCR7-) mediated retention of
lymphocytes in the lymph nodes, including na¨ ıve T cells and
central memory T cells, but not eﬀective memory T cells.
This signiﬁcantly reduces the inﬁltration of inﬂammatory
cells into the CNS [143, 144] and reduces the numbers of
autoreactive Th17 cells that are recirculating via the lymph
and blood to the CNS [145–147]. The second pathway
prohibits neuroinﬂammation via the modulation of the8 Clinical and Developmental Immunology
Figure 2: Multiple sclerosis immunopathogenesis and therapeutic targets. Immature dendritic cells (DCs) are central players in the innate
immuneresponseandareinvolvedinthemaintenanceofperipheraltolerancebypromotingthesuppressorTregandanti-inﬂammatoryTh2-
cell responses. Abnormally activated (mature) antigen-presenting DCs can be found in patients with multiple sclerosis (MS). This activation
results in the increased production of proinﬂammatory cytokines, which lead to the aberrant activation of Th1 and Th17 proinﬂammatory
responses. Activated encephalitogenic adaptive immune eﬀectors (such as Th1 cells, Th17 cells, CD8+ cells, and B cells) express surface
molecules that allow them to penetrate the blood-brain barrier and to enter the central nervous system (CNS). The presence of autoreactive
immune eﬀectors, together with abnormally activated CNS astrocytes and microglia, leads to the increased production of reactive oxygen
species,excitotoxicity,autoantibodyproduction,anddirectcytotoxicity,whichareallinvolvedinthedemyelinationandaxonalandneuronal
damage that is present in patients with MS. Potential therapeutic interventions at diﬀerent levels of the immunopathological cascade
are shown in the ﬁlled yellow boxes (cytotoxic T lymphocytes [CTL]; interferon γ [IFNγ]; IL2 receptor [IL2R]; major histocompatibility
complex class II [MHC II]; matrix metalloproteinases [MMPs]; nitric oxide [NO]; oligodendrocyte [ODG]; sphingosine 1-phosphate
receptor [S1PR]; transforming growth factor β [TGFβ]; tumor necrosis factor [TNF]; regulatory T cells [Treg]; vascular cellular adhesion
molecule 1 [VCAM1]; very late antigen 4 [VLA-4] (This ﬁgure was adapted and partly revised from [55].).Clinical and Developmental Immunology 9
S1PR1 expressed on oligodendrocytes, neurons, astrocytes,
and microglia [76, 148, 149]. Another oral immunomod-
ulatory drug Cladribine (2-chlorodeoxyadenosine) is a
synthetic chlorinated deoxyadenosine analog [150] that is
activated by intracellular phosphorylation in speciﬁc cell
types, resulting in preferential and sustained reduction of
peripheral T and B lymphocytes, mimicking the immune-
deﬁcientstatusofhereditaryadenosinedeaminasedeﬁciency
[151]. Orally administered cladribine shows signiﬁcantly
eﬃcacy in patients with RR-MS [152]. Relative to placebo,
oral cladribine reduces relapses by 55–58% and has an
impact on disability progression and all MRI outcome
markers in patients with RR-MS [152–154]. Nevertheless, to
exactly weight the beneﬁts of both novel immunomodultory
agents against the potential risks is necessary and must be
monitored continually.
These advances in identifying unique therapeutic targets
forMShaveinstigatednumerousphaseIIandphaseIIIclini-
caltrials,forexample,trialsofvariousmAbs,includingthose
directed against CD52 (alemtuzumab), CD25 (daclizumab),
and CD20 (rituximab), and trials of disease-modifying
therapies, such as teriﬂunomide, laquinimod, and fumarate
[135, 155]. For example, alemtuzumab, a humanized mAb,
targets the surface molecule CD52 on all T-cell populations
and other cellular components of the immune system, such
as thymocytes, B cells, and monocytes [156].
Oﬀner reported that estrogen and its derivatives exert
neuroimmunoprotective eﬀects against EAE and that E2
upregulates the expression of Foxp3 and Ctla4, which
contribute to the activity of Tregs, suggesting the thera-
peutic application of estrogen to MS [157]. Papenfuss et
al. also demonstrated that estriol (E3), a pregnancy-speciﬁc
estrogen, has therapeutic eﬃcacy in MS and EAE and they
conﬁrmed that E3 protects mice against EAE by inducing
DCs to increase their expression of inhibitory costimulatory
markers (PD-L1, PD-L2, B7-H3) and deviate towards a Th2
phenotype [158].
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear hormone receptor superfamily,
which includes receptors for steroids, retinoids, and thyroid
hormones, all of which are involved in the immune response
[159]. Natarajan et al. demonstrated that PPARγ agonists
inhibit EAE by blocking IL12 production, IL12 signaling,
and Th1 cell diﬀerentiation [160]. Kanakasabai et al. further
demonstrated that the PPARδ agonists ameliorate EAE by
blocking IFNγ and IL17 production by Th1 and Th17 cells.
The inhibition of EAE by PPARδ agonists is also associated
with reductions in IL12 and IL23 and increases in IL4 and
IL10 expression in the CNS and lymphoid organs. This
indicates that PPARδ agonists modulate the Th1 and Th17
responses in EAE, and suggests their use in the treatment of
MS and other autoimmune diseases [161].
Minocycline, an oral semisynthetic tetracycline antibi-
otic, can penetrate the CNS and has interesting pleiotropic
biological functions and neuroprotective eﬀects, including
in demyelinating diseases such as MS [55]. Nikodemova
et al. have shown that minocycline attenuates EAE in rats
by reducing T-cell inﬁltration into the spinal cord and
downregulating LFA-1 on T cells, but without modifying
the production of dominant cytokines [162]. Zabad et al.
demonstrated in a cohort study the impact of oral minocy-
cline on clinical and MRI outcomes and serum immune
molecules during the 24 months of open-label minocycline
treatment. No relapses occurred between months 6 and 24,
andthelevelsofthep40subunitofIL12wereelevatedduring
the 18 months of treatment, which might have counteracted
the proinﬂammatory eﬀects of IL12R. The downregulation
of MMP9 activity was reduced by minocycline treatment
[163].
Brines et al. have demonstrated that EPO mediates neu-
roprotection against experimental ischemic brain injury
[164]. Agnello et al. have shown that EPO exerts an anti-
inﬂammatory eﬀect that ameliorates EAE [165]. Yuan et al.
also demonstrated that EPO retains its immunomodulatory
capacity in both the periphery and the inﬂamed spinal cord
by promoting a massive expansion of Treg cells, inhibit-
ing Th17 polarization and abrogating the proliferation of
antigen-presenting DCs [166]. We observed signiﬁcantly
reduced levels of both Th1 and Th17 cells in the CNS and
a signiﬁcantly increased proportion of splenic Tregs in EPO-
treated Mog-EAE mice. We also demonstrated that MOG-
speciﬁc T-cell proliferation was suppressed in the EPO-
treated group [167].
The immunomodulatory mechanisms of immunomedi-
ated therapeutic agents are not fully understood. Here, we
report our current understanding of the immunomodula-
tory eﬀects of clinically proven and clinically tried agents,
and of potential candidate agents, such as decoy receptor 3
(DcR3). We have selectively reviewed their immunomodu-
lation in EAE and MS. Demjen et al. showed that the neu-
tralization of CD95L (FasL) promoted axonal regeneration
and functional improvement in an injured animal model,
suggesting that this therapeutic strategy may constitute a
potentfuturetreatmentforhumanspinalinjury[168].DcR3
is a recognized member of the TNFR superfamily and is pre-
dominantly expressed in tumor cells, allowing them to evade
immuneattack[169].DcR3isasolublereceptorthatbindsto
membersoftheTNFfamilyandcancompetitivelyinhibitthe
binding of TNF to TNFRs [170]. FasL, LIGHT, and TNF-like
molecule 1A (TL1A) are all conﬁrmed ligands of DcR3 [171,
172]. When DcR3 binds to FasL, it inhibits FasL-induced
apoptosis [169]. It has also recently been shown that DcR3
counteracts the eﬀects of Th17 cells by interfering with FasL-
Fas interactions [173]. We have demonstrated that DcR3
ameliorates EAE by directly counteracting inﬂammation
and downregulating Th17 cells in situ [174], implying that
DcR3 downregulates the Th17 response and inhibits the
inﬂammation of the CNS in situ during EAE by blocking
ligand-receptor interactions, such as Fas-FasL, DR2–LIGHT,
and/or DR3–TL1A. Therefore, we introduce DcR3, another
immunomodulatory molecule, as a potential candidate for
consideration in the clinical treatment of MS.
In summary (Figure 2), these immunomodulatory
agents and neuroprotective therapies for MS have great value
as clinical agents, to be tested in clinical trials or preclinical
studies, and in the development of novel therapeutic
strategies for MS [55].10 Clinical and Developmental Immunology
8. Concluding Remarks
MS is the most common disabling CNS disease in young
adults. It is characterized by recurrent relapses and/or pro-
gression, which are attributable to multifocal inﬂammation,
demyelination,andaxonalpathologywithinthebrainand/or
spinalcord[175].TheeﬀectorThcellsplayawell-recognized
role in the initiation of autoimmune tissue inﬂammation,
and these autoreactive eﬀector CD4+ T cells have an estab-
lishedassociationwiththepathogenesis ofthisdisorder[17].
However, in models thought to be driven by Th1 cells, mice
lacking the hallmark Th1 cytokine IFNγ were not protected
from EAE but tended to display enhanced susceptibility
to this disease [26]. The identiﬁcation of Th17 cells has
shed light on this apparent discrepancy. Like Th1 cells,
polarized Th17 cells have the capacity to cause inﬂammation
and autoimmune disease. A deﬁciency of the Th17-related
cytokine IL23, but not of the Th1-related cytokine IL12,
induces resistance to EAE, implying that Th17 cells are the
chief contributors to EAE/MS [28], whereas Th1 cells can
consistently transfer EAE disease [16, 17]. Komiyama et
al. demonstrated that EAE was signiﬁcantly suppressed in
Il17−/− mice, manifested as delayed onset, reduced maxi-
mum severity, ameliorated histological changes, and early
recovery [176]. However, the outcomes have varied when
the diﬀerentiation and/or functions of Th17 cells have been
blocked in clinical trials of human autoimmune diseases,
with notable success only in psoriasis and Crohn’s disease,
but negative results in relapsing/remitting MS. The strategy
of inhibiting the Th17 response has had even less support in
preclinical studies in animal models [177].
These data raise the questions of whether MS is mediated
solely by Th1 cells or solely by Th17 cells, whether it is
mediated by both pathways, or whether perhaps it is medi-
ated by neither pathway [175]. There is growing evidence
that autoreactive T cells (particularly Th1 and Th17 cells)
participate inthepathophysiology ofMS.Althoughtheexact
roles of Th1 and Th17 cells in the development of MS
lesions are not well understood, it appears that both these
eﬀector T-cell populations can cause CNS inﬂammation and
demyelinating lesions in MS and EAE [50, 178].
Our increasing understanding of the immunopathogenic
roles of Th1, Th2, and Th17 cells and Tregs in MS/EAE
should facilitate the development of novel immunomodula-
tory therapeutic approaches to MS [179, 180].The treatment
of MS has always been hampered by the untoward adverse
eﬀects caused by immunosuppression with agents such as
natalizumab [128]. Currently approved disease-modifying
treatments achieve their eﬀects primarily by blocking the
proinﬂammatory response in a nonspeciﬁc manner. Their
limited clinical eﬃcacy calls for a more diﬀerentiated and
speciﬁc therapeutic approach. We can conﬁdently say that
IFNβ, GA, and mitoxantrone are fairly clinically eﬀective
for MS patients. The addition of estrogen(s) or minocycline
has also shown beneﬁts in the treatment of MS. We have
established the protective eﬀects of DcR3 and EPO against
EAE [174, 181], but further evidence is required before
they can be used clinically for the treatment of MS. More
immunomodulatory therapeutic agents are currently in
clinicaltrials,includingﬁngolimod(FTY720),alemtuzumab,
and rituximab add-on therapies [182]. The extensive clinical
application of these potential novel immunomodulatory
therapeutic agents will be under close scrutiny in the near
future.
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